Sign in7 stories
Shareholders holding a majority of votes present approved all six director nominees, an updated incentive compensation plan, and the auditor's reappointment at the September 9 meeting.
SEC filing
The clinical-stage biotech disclosed a shelf-based stock sale agreement dated August 21, 2026, alongside updated data on its lead osteosarcoma candidate OST-HER2.
SEC filing (2)
The company entered a sales agreement on August 21, 2026 letting it sell shares over time to fund clinical development and other priorities.
SEC filing
Company disclosed terms of a July 31 Leonite settlement and an August 10 securities purchase agreement for senior secured convertible notes.
SEC filing (2)
The company will issue the shares on or about August 6, 2026 to satisfy amounts owed under a secured note issued to Leonite in June 2026.
SEC filing
The company ended its ATM facility with B. Riley Securities and JonesTrading, having sold only a small fraction of the authorized amount.
SEC filing
The Delaware biotechnology company disclosed a new notice of exempt securities offering to the SEC, with $1.6 million already sold as of the filing date.
SEC filing